Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing.

@article{Schiffmann2007WeeklyER,
  title={Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing.},
  author={Raphael Schiffmann and Hasan Askari and Margaret M Timmons and Chevalia J Robinson and William Benko and Roscoe O. Brady and Markus Ries},
  journal={Journal of the American Society of Nephrology : JASN},
  year={2007},
  volume={18 5},
  pages={1576-83}
}
This study was performed to determine whether adult male patients with Fabry disease who demonstrate a continuing decline in renal function despite 2 to 4 yr of conventionally dosed agalsidase alfa therapy (0.2 mg/kg every other week [EOW]) show an improved slope of decline with weekly administration using the same dosage. Eleven (27%) of 41 adult male patients with Fabry disease who participated in long-term agalsidase alfa clinical trials and who had demonstrated a slope of decline in… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 50 extracted citations

Similar Papers

Loading similar papers…